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Rats are a standard experimental animal for cancer bioassay and toxicological research for chemicals. Although the
genetic analyses were behind mice, rats have been more frequently used for toxicological research than mice.
This is partly because they live longer than mice and induce a wider variety of tumors, which are morphologically
similar to those in humans. The body mass is larger than mice, which enables to take samples from organs for
studies on pharmacokinetics or toxicokinetics. In addition, there are a number of chemicals that exhibit marked
species differences in the carcinogenicity. These compounds are carcinogenic in rats but not in mice. Such examples
are aflatoxin B1 and tamoxifen, both are carcinogenic to humans. Therefore, negative mutagenic/carcinogenic
responses in mice do not guarantee that the chemical is not mutagenic/carcinogenic to rats or perhaps to humans.
To facilitate research on in vivo mutagenesis and carcinogenesis, several transgenic rat models have been established.
In general, the transgenic rats for mutagenesis are treated with chemicals longer than transgenic mice for more exact
examination of the relationship between mutagenesis and carcinogenesis. Transgenic rat models for carcinogenesis are
engineered mostly to understand mechanisms underlying chemical carcinogenesis. Here, we review papers dealing
with the transgenic rat models for mutagenesis and carcinogenesis, and discuss the future perspective.
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In modern industrial society, humans are inevitably ex-
posed to a variety of chemicals. These chemicals are
mostly important to sustain the society and improve
the quality of life. Antibiotics and other pharmaceuti-
cals are such examples and they significantly prolong
longevity and improve peoples’ health conditions. How-
ever, there are a number of chemicals that might have
adverse effects on humans. Such examples are cigarette
smoke, air pollutants and contaminants in water and
food. These adverse chemicals are sometimes linked to
human cancer. Therefore, international organizations
such as Organization for Economic Co-operation and
Development (OECD) or World Health Organization
(WHO) set up guidelines to evaluate the genotoxic and
carcinogenic risk of chemicals [1]. Genotoxicity is
regarded as an important biomarker for carcinogenesis* Correspondence: nohmi@nihs.go.jp
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(http://creativecommons.org/publicdomain/zebecause many human carcinogens are reactive to DNA
and induce mutations in the target organs of carcino-
genesis [2]. In mechanisms, mutations of many onco-
genes and suppressor oncogenes are deeply involved in
a variety of human cancer [3]. In general, it is believed
that DNA reactive carcinogens impose cancer risk on
humans even at very low doses [4]. Therefore, regulatory
agencies in many countries pay strong attention to identify
DNA reactive genotoxic agents to reduce the cancer risk
related to exposure to environmental chemicals.
In 1970’s and 1980’s, genotoxicity of chemicals was
examined mainly by in vitro short-term assays with
bacteria and cultured mammalian cells. Although bac-
terial mutation assays, i.e., Ames test, is still the gold
standard to identify DNA reactive genotoxic chemicals,
in vitro genotoxicity assays have some limitations. Bac-
teria and most of cultured mammalian cells do not pos-
sess enough metabolic capacity to activate or inactivate
chemical carcinogens [5]. So, rat liver homogenate, i.e.,
S9, is adopted to mimic the mammalian metabolism.
However, some chemical carcinogens such as urethanele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ciency of S9 to activate the chemicals to ultimate muta-
gens [6]. On the other hand, non-carcinogenic chemicals
such as 2,6-diaminotoluene (2,6-DAT) give positive results
in Ames test probably because S9 does not have enough
detoxication capacities [7, 8]. Recent survey revealed that
in vitro mammalian genotoxicity assays such as chromo-
some aberration assays, gene mutation assays and micro-
nucleus assays give many false positives, i.e., positives in
the assays but negatives in rodent cancer bioassays [9].
Thus, in vivo genotoxicity is regarded more important
than in vitro results in terms of decision making whether
the particular chemical is genotoxic and carcinogenic to
humans or not.
Classical in vivo genotoxicity assays are, however, very
time consuming and target organs for the assays are
quite limited. For example, “mouse spot test” uses devel-
oping embryo and detects mutations in the genes con-
trolling the pigmentation of coat color of mice [10]. This
test has been adopted into OECD Guidelines for the
Testing of Chemicals as Test No. 484. If mutations are
induced in the genes that control the pigmentation of
coat color, the offspring will have spots of changed color
in the coat. The frequency of such spots in the treated
mice is compared to that of the spots in untreated mice.
Although this assay certainly detects mutations in mice
in vivo, the target organ for mutagenesis is only melano-
blasts in embryo. Because very few people conduct the
assays nowadays, it has been deleted from OECD test
guidelines in 2014. Another in vivo genotoxicity assay,
that is, “Mouse Dlb-1 mutation assay”, detects mutations
at the Dlb-1 locus in colon, which determines the ex-
pression of the binding site for the lectin Dolichos
biflorus agglutinin [11]. C57BL/6J × SWR F1 mice are
exposed to chemicals and the mutants are detected as
clones of epithelial cells not stained with a peroxidase
conjugated with the agglutinin. The assay is capable of
identification of mutagens in colon but is not applicable
to other organs such as liver.
To circumvent the above limitations, transgenic mice
for mutagenesis have been developed in late 1980’s and
1990’s. Big Blue mice, Muta Mice and gpt delta mice are
representative transgenic mice for mutagenesis and they
use lambda phage as a vector having reporter genes for
mutations [12–15]. The phages are recovered from the
genomic DNA of mice by in vitro lambda phage pack-
aging reactions and in vivo mutations are detected after
introduction of the rescued phage to indicator Escheri-
chia coli (E. coli). Because the vector DNA having the
reporter genes is recovered from the mouse genome to
bacteria, they are called shuttle vectors. Although the re-
porter genes are bacteria or phage origin, the assays
allow detection of mutations in any organ of mice such
as liver, lung, bone marrow or testis. In addition, DNAsequence analysis can reveal mutation spectra associated
with chemical exposure. About 10 years later from the
development of transgenic mice, transgenic rats were de-
veloped because rats are more frequently used for cancer
bioassays. Currently Big Blue rats having lambda LIZ
and gpt delta rats having lambda EG10 are commercially
available and widely used for in vivo mutagenesis [7, 16,
17]. Therefore, we focus on these two in vivo assays and
discuss what has been revealed by the assays (Table 1).
In the later part of this review, we review several trans-
genic rat models for chemical carcinogenesis (Table 2)
and discuss the future perspective.
Transgenic rats for mutagenesis
Before establishment of transgenic rats for mutagenesis,
there was a gap between in vivo genotoxicity assays and
rodent cancer bioassays in terms of animal species. In
vivo genotoxicity assays such as chromosome aberration
test and micronucleus test have been conducted more
frequently with mice than with rats because of the ease
of handling and clearer genetic background. In contrast,
rodent cancer bioassays have been conducted with rats
more frequently than mice because of the lower fre-
quency of spontaneous tumors and larger body mass.
This species difference leads to discrepancy of test
results between mice in mutagenesis and rats in carcino-
genesis. Aflatoxin B1 gives negative or weakly positive
results in genotoxicity with mice while rats give strong
positives in carcinogenicity assays [18]. To fill in the gap,
transgenic rats have been engineered. Nowadays, they
are used as a standard tool to examine the mutagenicity
of chemicals in the target organs of carcinogenesis.
Assay systems
Although both Big Blue rats and gpt delta rats use
lambda phage as vectors of reporter genes, the assay sys-
tems are different as described below.
Big blue rats
Big Blue rats were generated by microinjection of
lambda LIZ phage DNA into fertilized eggs of Fischer
344 (F344) rats [16]. In addition, the embryonic fibro-
blasts, i.e., Rat 2 cells, were established for an in vitro
transgenic assay [19]. Originally, color selection with lacI
was adopted for mutant detection but later more con-
venient cII selection was applied to Big Blue rat assays
[20] (Fig. 1a, b). The gene lacI encodes a repressor pro-
tein LacI, which suppresses the expression of beta-
galactosidase in E. coli. Therefore, inactivation of lacI by
mutations results in the expression of beta-galactosidase
and production of blue plaque in the presence of X-gal,
while wild-type lacI leads to colorless plaques. However,
this selection is time consuming and expensive because
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a b
Fig. 1 Mutant selections for Big Blue rats. a lacI selection. When LacI,
the repressor protein of the lac operon, is active, it represses the
expression of beta-galactosidase, which leads to colorless plaques.
When the lacI gene is inactivated by mutations, beta-galactosidase
is expressed, which leads to blue plaques. b cII selection. The cII
protein is the critical switch in the lytic/lysogenic cycles of lambda
phage. It activates the expression of the lambda cI (repressor) and
int (integrase) genes, which are required for the establishment of
lysogeny. The cII protein is negatively regulated by host E. coli Hfl
protease, which digests the cII protein. In the hfl- background, the
cII level is high, and therefore the lambda becomes lysogen. Only
cII mutants can enter a lytic cycle and make plaques at 24 °C. The
cI- mutants can’t enter the lytic cycle at this temperature. Therefore,
the cII selection for Big Blue rats is conducted at 24 °C
Nohmi et al. Genes and Environment  (2017) 39:11 Page 19 of 32the CII protein induces the expression of the cI and the
int genes that are required for a phage lysogeny [21]. In
the hfl− E. coli, phages with active cII gene can’t enter a
lytic cycle and form no plaques because of the deficient
in Hfl protease. This protease degrades CII protein and
lets the phage enter a lytic cycle. The only phages with
inactive cII mutants can make plaques with the E. coli
hfl− cells. Thus, this is a positive selection, and much
more convenient and less expensive than the original
lacI assay. The coding size of lacI is 1080 bp while that
of cII is 294 bp, which makes cII more attractive for de-
termination of mutation spectrum.
Because cII was introduced several years after the ori-
ginal lacI color selection has been established, the level
of spontaneous mutations and sensitivity to chemically-
induced mutagenesis were compared between the re-
porter genes. Chen et al. [22] report that spontaneous
mutation frequency of cII in liver is markedly higher
than that of lacI (80 × 10−6 vs 10 × 10−6). Stuart et al.
[23] also report that the mutation frequency of cII in
colon mucosa is higher than that of lacI (78 × 10−6 vs
23 × 10−6). The cII gene has six G:C base pairs between
nucleotide number 179 and 185, which is one of the
hot spots of spontaneous mutagenesis. The high back-
ground makes smaller fold increases in mutation frequency
after chemical treatments with alpha-hydroxytamoxifen
and tamoxifen [22]. However, Gollapudi et al. [20] report
that there is no significant difference in spontaneous and
dimethyl nitrosamine (DMN)-induced mutation frequen-
cies in liver between cII and lacI of Big Blue rats (99 × 10−6
vs 85 × 10−6 for spontaneous and 415 × 10−6 vs 400 × 10−6
for DMN.)
In both lacI and cII, deamination of 5-methylcytosine
(5-MeC), which results in G:C to A:T transitions, is a
major source of spontaneous mutations. Full methyla-
tion of cII and lacI in Big Blue rats is reported in bone
marrow, bladder, liver, spleen and breast [24]. Spontan-
eous lacI mutation frequencies are lower in bone mar-
row and bladder compared to liver, which can’t be
explained by the status of methylation of 5-MeC [25,
26]. Monroe et al. [24] suggest, therefore, that other
mechanisms besides deamination of 5-MeC contribute
to spontaneous mutagenesis in Big Blue system.
Because lacI is not an endogenous gene but a bacterial
gene, the sensitivity of lacI and an endogenous gene, i.e.,
Hprt, in spleen was compared in Big Blue rats. Both
genes were responded to 7, 12-dimethylbenz[a]anthracene
(DMBA) [26, 27], N-hydroxyacetylaminofluorene [28] and
thiotepa, an anticancer drug [29], and the mutation fre-
quencies were increased. However, spontaneous mutation
frequencies of Hprt were about 10 times lower than those
of lacI [27]. Thus, the fold increases were larger in Hprt
than in lacI. For example, the mutation frequency of Hprt
was increased more than 10 fold by thiotepa treatments(3.5 × 10−6 vs 41.1 × 10−6) while that of lacI was increased
about four fold by the same treatment (34.8 × 10−6 vs
140.9 × 10−6) [29]. In addition, the mutation spectra were
different where Hprt recovered a fraction of large dele-
tions not found among lacI mutants [29].
In summary, lacI and cII can be regarded as effective
surrogate genes for in vivo mutations while spontaneous
mutation frequency of cII may be higher than that of
lacI. Caution should be payed that deletion mutations
may be missed by the surrogate genes.
gpt delta rats
gpt delta rats were generated by microinjection of
lambda EG10 DNA into fertilized eggs of Sprague-
Dawley (SD) rats [17]. The SD gpt delta rats were later
crossed with F344 rats for 15 generations, thereby estab-
lishing F344 gpt delta rats [7]. Two distinct selection sys-
tems are available for gpt delta mice and rats (Fig. 2a).
One is gpt selection for detection of point mutations and
the other is Spi- selection for deletions [15, 30]. The gpt
gene is a bacterial counterpart of Hprt and encodes
guanine phosphoribosyl transferase. When the gpt gene
is inactivated by mutations, the E. coli host cells pos-
sessing plasmid carrying mutated gpt gene can survive
on plates containing 6-thioguanine (6-TG) while those
a b
Fig. 2 Mutant selection for gpt delta rats. a gpt selection. The E. coli
gpt gene encodes guanine phosphoribosyl transferase, which
attaches a phosphoribose to 6-TG. The phosphoribosylated 6-TG
is further phosphorylated and finally incorporated into DNA.
Incorporation of 6-TG is toxic to E. coli and cell death is induced.
Therefore, only when the gpt gene is inactivated by mutations,
E. coli can make colonies on a plate containing 6-TG. b Spi- selection.
The wild-type lambda phages lyse E. coli, thereby making phage
plaques. However, if the E. coli chromosome harbors P2 phage
DNA, which is called P2 lysogen, the wild-type lambda phage can’t
lyse P2 lysogen. Only the defective lambda phage whose red and
gam genes are inactivated can lyse P2 lysogen. The resulting plaques
are called P2 plaques. Because the red and gam genes are localized in
lambda genome side by side, the inactivation of two genes are most
likely induced by deletions in the region
Nohmi et al. Genes and Environment  (2017) 39:11 Page 20 of 32harboring plasmid carrying the wild-type gpt gene die
because they phosphoribosylate 6-TG and incorporate
6-TGMP into DNA. Therefore, the gpt selection is a
positive selection.
Spi- stands for sensitive to P2 interference [31] (Fig. 2b).
This selection allows selective detection of deletion mu-
tants of lambda phage. In wild-type E. coli, the wild-type
lambda phage lyses the E. coli, thereby forming phage pla-
ques. However, if E. coli chromosome possesses P2 phage
DNA, that is called P2 lysogen, the wild-type lambda
phage can’t form plaques. This phenomenon is called “P2
interference”. However, when two genes of lambda phage,
i.e., the red and gam genes, are simultaneously inactivated,
the defective phage can make plaques in P2 lysogen. The
plaques are called Spi- plaques. Since the red and gam
genes are located side by side in the lambda DNA, the
simultaneous inactivation of two genes are most likely in-
duced by deletion of the region containing the two genes.
The unique feature of Spi- selection is specific detection of
deletion mutations including frameshift mutations.
The transgene lambda EG10 having the gpt gene and
the red/gam genes is located in the chromosome four of
gpt delta rats. The exact location of the integration site
in the rat genome was determined by next generationDNA sequencer (NGS) [32]. About 72 kb genomic se-
quence was deleted during integration of the transgene
and smaller genetic rearrangements were also induced
by the integration. Unlike gpt delta mice, which have
lambda EG10 in both chromosome 17, gpt delta rats are
heterozygous where lambda EG10 is integrated in only
one allele of chromosome 4. This is because homozy-
gous gpt delta rats are defective in tooth development
and can’t survive after weaning. Specific PCR primers
that can be used to amplify the DNA sequence between
rat chromosome and the integrated lambda EG10 are
available. They can be used to distinguish between wild-
type rats and gpt delta rats. The average spontaneous gpt
and Spi- mutant frequencies in liver are 4.5 × 10−6 and
2.7 × 10−6, respectively [33]. The frequencies are signifi-
cantly lower than those of the lacI and cII genes. The
low spontaneous mutant frequencies of gpt and Spi- are
similar to those of gpt delta mice.
Issues that have been examined by transgenic rat assays
Organ/tissue specificity
An important feature of chemical carcinogens is the
organ specificity. They induce cancer in specific organs,
which are called target organs for carcinogenesis. Afla-
toxin B1, aristolochic acid and o-toluidine are all potent
human carcinogens but they induce cancer in different
organs, i.e., liver by aflatoxin B1, kidney by aristolochic
acid and bladder by o-toluidine [34–36]. Thus, an inter-
esting question for transgenic rat assays for mutagenesis
is whether mutations can be identified in the target or-
gans for carcinogenesis.
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP) is a heterocyclic amine in cooked food and ad-
ministration of PhIP in diet causes cancer in the pros-
tate in male rats and in the mammary glands in
females [37, 38]. It was examined, therefore, whether
PhIP induces mutations in the target organs in a sex
specific manner. PhIP-induced mutations were identi-
fied in mammary glands of female rats [39, 40] and
prostate in males [41, 42]. These results suggest the
causal link between mutagenesis and carcinogenesis
induced by PhIP in mammary glands and prostates.
However, mutations in prostate were identified not
only in ventral prostate where cancer is induced but
also in dorsolateral and anterior lobe where cancer is
sparingly induced [41]. This raised a question as to
what factors define the lobe specificity of PhIP-
induced carcinogenesis. Interestingly, PhIP acts as a
promoter and induces cell proliferation only in the
ventral prostate [41]. Thus, PhIP may be an organ-
and lobe-specific promoter while it acts as an initiator
in all three lobes
PhIP induces colon cancer much more frequently in
male rats than in females [43]. Therefore, colon
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rats. It was revealed that mutations were almost equally
induced in both sexes [44, 45]. The mutation spectra in-
duced by PhIP were also similar in both sexes, i.e., one
base deletions including the guanine deletion at 5′-
GGGA-3′ [44]. These results suggest that factors other
than mutagenesis strongly contribute to PhIP-induced
carcinogenesis and also that the factors may determine
the sex-specific induction of colon cancer by PhIP.
The relationship between mutagenesis and carcinogen-
esis has been examined even at the sub-organ level as in
the case of PhIP in the prostate. Tris(2,3-dibromopro-
pyl)phosphate (TDBP) induces tumors specifically in
outer medulla in the kidney of rats [46]. Mutations were
examined in the inner medulla, outer medulla and cor-
tex of kidney, and the mutation frequency was in the
order of cortex followed by outer medulla (the target
site) and inner medulla [47]. The highest mutation
induction does not coincide with the localization of tu-
mors. However, cell proliferation is increased specifically
in the outer medulla after TDBP treatment [46, 48].
Thus, it was concluded that combined effects of cell pro-
liferation and induction of mutations are responsible for
sub-organ-specific tumor formation by TDBP.
Ochratoxin A, a mycotoxin, also induces renal tumors
in rats specific in S3 segment of the proximal tubules
[49]. Unlike TDBP, mutations are induced only in the
outer medulla, which is primarily occupied by the S3
segment of the proximal tubules [50]. No mutations
were detected in the cortex. Thus in this case, specific
induction of mutations in outer medulla might account
for the sub-organ-specific induction of tumors in rats
(See more in Genotoxic versus non-genotoxic carcino-
gens section).
Phenacetin, an analgesic drug, induces tumors in kid-
ney but not in liver [51]. The in vivo mutagenesis in
kidney and liver was examined with SD gpt delta rats
fed with diet containing phenacetin for 26 and 52 weeks
[52]. Mutations were detected in both kidney and liver
and the mutation frequency was much higher in liver
(non-target organ) than in kidney (target organ). The
results suggest the intensity of mutagenicity does not ne-
cessarily correlate with the induction of tumor formation.Carcinogens versus structurally-related non-carcinogens
Chemical carcinogens excert the adverse effects depned-
ing on the chemical structures. Even the structures are
similar, their carcinogenicity is sometimes completely
different. Transgenic rats for mutagenesis were exam-
ined for their ability to distinguish mutagenicity of struc-
tural isomers, i.e., one is a carcinogen and the other is a
non-carcinogen. 2,4-Diaminotoluene (2,4-DAT) is an
intermediate in chemical industry but induces hepatictumors in male and female rats and mammary and sub-
cutaneous tumors in female rats [53]. The isomer 2,6-
DAT is an intermediate of dyes and rubber chemicals
and is not carcinogenic in rats and mice despite the
structural similarity to 2,4-DAT [54]. Interestingly, both
DATs are mutagenic in Ames Salmonella strains [7],
suggesing the potential mutagenicity of both chemicals.
The in vivo mutagenicity of 2,4-DAT and 2,6-DAT was
examined in liver and kidney of male gpt delta rats [7].
The rats were fed 2,4-DAT or 2,6-DAT in diet for
13 weeks and the mutations were examined. Only 2,4-
DAT induced gpt and Spi- mutations in liver but not in
kidney. 2,6-DAT was negative in gpt and Spi- assays in
liver and kideny. The results suggest that in vitro muta-
genicity should be carefully examined by in vivo muta-
genicty assay. The mutagenicity of 2,4-DAT but not
2,6-DAT in liver of gpt delta rats was also reported by 4
weeks administration of gavage [55].
Tamoxifen is a nonsteroid antiestrogen that is used as
adjuvant therapy for breast cancer. However, tamoxifen
is carcinogenic in liver in rats [56]. The structural
analogue toremifen is not carcinogenic [57]. To examine
whether transgenic rats distinguish two compounds in
terms of mutagenesis, female F344 gpt delta rats were
treated with either tamoxifen or toremifen [58]. Tamoxi-
fen significantly enhanced gpt and Spi- mutation fre-
quencies in the liver. The treatment did not increase the
mutation frequencies in the kidney, a non-target organ
for carcinogenesis. Toremifen did not increase gpt and
Spi- mutation frequencies in liver and kidney. The re-
sults clearly indicate that tamoxifen is mutagenic in the
target organ for carcinogenesis but the strustural
analogue toremifen is not.
6-p-Dimethylaminophenylazobenzthiazole (6BT) is a
potent liver carcinogen in rats [59]. It induces malignant
liver tumors after 2-to-3 months of dietary administration
in a riboflavin-deficient diet. In contrast, the analogue 5-
p-dimethylaminophenylazobenzthiazole (5BT) gives no
tumors after 6 month administration. Both chemicals are
potent mutagens in Ames Salmonella strains [60]. The
mutagenicity of 6BT and 5BT was examined with Big Blue
rats and unexpectedly both were mutagenic in liver [61].
Thus, mutagenicity did not account for the marked
difference of the carcinogenicity of two closely-related
compounds. It is speculated that differential cell pro-
liferation effects on oval cells in liver may explain the
difference. 6BT induces the proliferation of ovall cells
by either gavage or in diet while 5BT is inactive in this
respect. Oval cells may be progenitor cells for hepato-
cellular carcinoma [62].
Genotoxic versus non-genotoxic carcinogens
A key question for evaluation and regulation of chemical
carcinogens is whether mutations are involved in the
Nohmi et al. Genes and Environment  (2017) 39:11 Page 22 of 32mechanisms of carcinogenesis. If the chemical induces
mutations in the target organ, thereby causing carcino-
genesis, the chemical is classified as “a genotoxic car-
cinogen”, which has no threshold or safety dose for the
action [4]. In contrast, when the chemical dose not
induce mutations in the target organ despite the car-
cinogenicity, the chemical is classified as “a non-
genotoxic carcinogen”, which has threshold or safety
dose and can be used in the society below the safety
dose. If the chemical is judged as a genotoxic carcino-
gen, the chemical is not be considered acceptable for use
as food additives, pesticides or veterinary drugs [63, 64].
Several carcinogenic compounds in food were exam-
ined for the mutagenicity in the target organs for car-
cinogenesis with gpt delta rats [63]. It was revealed that
citrinin and 3-monochloropropane-1,2-diol (3-MCPD)
were negative, and hence they were classified as non-
genotoxic carcinogens [65, 66]. Citrinin is a food-
contaminated mycotoxin and induces renal tumors in
rats [67]. It may induce tumors via cell cycle progression
but not genotoxicity [65]. 3-MCPD is regarded as a rat
renal and testicular carcinogen [68] and is mutagenic in
Salmonella and E. coli strains for mutagenicity assays
[69]. The fatty acid esters of 3-MCPD are generated dur-
ing food processing and exert renal toxicity [70]. The es-
ters are metabolized to 3-MCPD in vivo [71]. Because of
the negative mutagenicity in vivo, 3-MCPD and the fatty
acid esters are judged as non-genotoxic carcinogens
[66]. On the other side, estragole [72], madder color [73]
and methyleugenol [74] were positive in the transgenic
assay and thus mutagenicity may participate in the car-
cinogenesis. Estragole is a natural organic compound
and frequently used as a flavoring food additive, but is
carcinogenic in liver of mice [75]. Despite the in vivo
mutagenicity, estragole is not mutagenic in Salmonella
and E. coli strains for mutagenicity assays [76]. Madder
color is a dye and a potent carcinogen in kidney and
liver in rats [77], and thus its use as a food additive has
been banned in Japan in 2004. Methyleugenol is a fra-
grance and flavoring agent but is a hepatocarcinogen in
F344 rats [78].
Malachite green is a dye that has been widely used as
an antifungal agent in fish industry, and leucomalachite
green is a reduction product and a major metabolite of
malachite green [79]. Malachite green induces adenoma
and/or carcinoma in thyroid gland, liver and mammary
gland of female F344 rats and leucomalachite green in-
duces adenoma in the testis of male rats [80]. Female
Big Blue rats were fed leucomalachite green for 4, 16 or
32 weeks and mutations were analyzed in Hprt in spleen,
micronucleus formation in bone marrow and lacI muta-
tion in liver [81]. No increases were observed in Hprt
mutation frequency and micronucleus formation. About
three fold increases in lacI mutant frequency wereobserved in rats treated for 16 weeks [79]. DNA adduct
levels increased in liver of rats. However, the following
mutation spectrum analysis indicated that the apparent
increase in mutation frequency was due to expansion of
spontaneous mutations [81]. It is still enigmatic how
malachite green and leucomalachite green induce tu-
mors in rats.
Ochratoxin A [49], a mycotoxin, is an interesting
agent because it induces Spi- mutations but not gpt
[50, 82]. It induces Spi- mutations in the target site of
carcinogenesis, i.e., the outer medulla of kidney, when
male gpt delta rats were treated with ochratoxin A.
Large deletions with the size of more than 1 kb are in-
duced by the treatment. Experiments with p53 defi-
cient gpt delta mice suggest that Spi- mutant
frequency, but not gpt, was increased by ochratoxin A
treatment [83, 84]. No mutagenicity was observed in
p53 proficient mice. It appears that double-strand
breaks in DNA are induced in the target site of kidney
of rats, which leads to large deletions. It is puzzling,
however, why gpt mutations are not induced. When
DNA is damaged, gpt mutations are usually more fre-
quently induced compared to Spi- mutations. If ochra-
toxin A induces DNA adducts, it should induce gpt
mutations as well as Spi- mutations. It is tempting to
speculate, therefore, that ochratoxin A may interact
with proteins involved in DNA replication, repair or
chromosome segregation, thereby inducing double-
strand breaks in DNA. If so, ochratoxin A may not be
a genotoxic carcinogen although it induces mutations
in the target organ of carcinogenesis.
Threshold or low dose effects
Although it is supposed that genotoxic carcinogens have
no thresholds or safety level, the following experiments
exhibit no effective dose levels for in vivo mutations of
genotoxic carcinogens. Male Big Blue rats were fed a
diet containing 0.001, 0.01, 0.1, 1, 10 or 100 ppm of 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)
for 16 weeks and the lacI mutation frequency and gluta-
thione S-transferase placental form (GST-P) positive foci
in the liver were examined [85]. MeIQx is a heterocyclic
amine formed during cooking and induces liver tumors
in rats [86]. The mutation frequencies significantly in-
creased at doses of 10 and 100 ppm, and GST-P positive
foci significantly increased at a dose of 100 ppm. No
statistical increases in both frequencies were observed,
however, at lower doses, indicating the existence of no
effective doses for mutagenesis and carcinogenesis.
Similarly, male Big Blue rats were administered with
potassium bromate (KBrO3) in drinking water at con-
centrations of 0, 0.02, 0.2, 2, 8, 30, 125 and 500 ppm for
16 weeks [87]. The lacI mutation in the kidney was
induced only at a concentration of 500 ppm. No
Nohmi et al. Genes and Environment  (2017) 39:11 Page 23 of 32mutagenicity was detected at 125 ppm or lower doses.
Histopathological changes in renal tubular cells were
observed at doses of 125 and 500 ppm but not at
30 ppm or lower doses. 8-oxoguanine in DNA was
formed only at a dose of 500 ppm. KBrO3 is an oxidiz-
ing agent and used as a maturing agent for flour and as
a dough conditioner [68]. However, it induces renal cell
tumors in male and female rats after oral administra-
tion for 2 years in the drinking water [88]. The results
suggest that there may be safety dose for the genotoxic
carcinogen.
Cyproterone acetate (CPA) is an antiandrogenic drug
that is used for women in long term treatments of excel
androgen levels. However, it induces liver tumors in rats
[89]. Female Big Blue rats were treated with CPA at a
single dose of 0, 5, 10, 20, 40, 80 and 100 mg/kg and the
lacI mutation frequency was determined in the liver 2
weeks after the last treatment. Significant increase in
mutation frequency was observed at a dose of 10 mg/kg
or higher, and no mutations were induced at a dose of
5 mg/kg [90]. Because high amounts of DNA adducts
were formed at the non-effective dose of 5 mg/kg, it was
assumed that the mitotic activity required for conversion
of DNA adducts to mutation was not sufficiently strong
at the dose.
Collectively, these results suggest the existence of no-
effective dose for mutagenesis in the target organs for
carcinogenesis even for mutagenic carcinogens. It re-
mains uncertain, however, the sensitivity to detect the
mutations is high enough to analyze the subtle increase
in mutation frequencies. It is suggested that no-effective
levels for mutagenesis vary depending on the in vivo
models and also that the lower no-effective levels are de-
tected with lower spontaneous mutation frequencies
[91]. To detect the no-effective levels, mathematical
models such as Points of Departure (PoD) have been
proposed [92].
Multiple exposure or chemoprevention
Genotoxic effects of chemicals are sometimes enhanced
or attenuated by dietary supplements. In addition,
people are exposed to multiple chemicals in real life.
Therefore, they may exert additive or synergistic effects
on the genotoxic effects. Transgenic rats for mutagenesis
have been utilized to examine the combined genotoxic
effects of more than one chemical in vivo.
Ellagic acid, green tea and diallyl sulfide (DAS) were
examined for the chemo preventive effects against N-
nitrosomethylbenzylamine (NMBA)–induced mutations
in the esophagus of Big Blue rats [93]. Addition of ellagic
acid in diet, replacing drinking water with green tea or
gavage of DAS significantly reduced the mutagenicity of
NMBA. In contrast, 5 % ethanol to the drinking water
enhanced the mutagenicity.Endogenous estrogen status and addition of genistein,
a phytoestrogen, were examined for the modulating ef-
fects on DMBA-induced mutation in liver of Big Blue
rats [94]. Ovariectomized female rats exhibited higher
mutation frequencies than the intact rats, suggesting the
endogenous ovarian hormones may have an inhibitory
effect on liver mutagenesis by DMBA. Dietary supple-
ment of genistein in the ovariectomized and the intact
rats did not alter the spontaneous and induced muta-
tions in liver. Ovariectomized female Big Blue rats were
also used to examine the modulating effects of daidzein,
genistein and 17-beta-estradiol on DMBA-induced muta-
genesis in the mammary glands [95] and uterus [96]. Daid-
zein and genistein are major constituents of isoflavones
and interact with the alpha and beta estrogen receptors in
the mammary glands. Daidzein, genistein and 17-beta-
estradiol each did not significantly change DMBA-induced
mutagenesis in the mammary glands and uterus.
Conjugated linoleic acid is a mixture of heat-derivatives
of linoleic acid, and is shown to be protective against het-
erocyclic amine-induced carcinogenesis [97]. Antimuta-
genic effects of conjugated linoleic acid was examined in
kidney of male and female Big Blue rats treated with PhIP
[98]. Conjugated linoleic acid reduced PhIP-induced mu-
tations of female rats but not those of male rats. There-
fore, the protective effects are sex-dependent.
High intake of sucrose is associated with increased
risk of colon cancer [99]. Co-mutagenic effects of su-
crose were examined in colon of 2-amino-3-methylimi-
dazo[4,5-f]quinoline (IQ)-treated Big Blue rats [100].
Sucrose and IQ increased the mutation frequencies and
the combined treatment with sucrose and IQ was addi-
tive, indicating that sucrose and IQ induce mutations
independently. It is worth noticing that sucrose is mu-
tagenic in vivo [101], which will be discussed more
detail below (Sweet diet section). On the other hand,
dietary restriction may delay aging and age-related
diseases. The effects of dietary restriction on PhIP-
induced mutation in the distal colon were examined
[102]. However, the restriction did not alter the mutation
frequency in male and female Big Blue rats. To examine
the interactions between tobacco smoking and asbestos
exposure, Big Blue rats were exposed to benzo[a]pyrene
(BP) and amosite intratracheally and mutations were ana-
lyzed in the lung of Big Blue rats. Combined instillation of
amosite and BP exhibited a highly significant synergistic
effect [103]. The mutation frequency of BP was enhanced
more than two times when combined with amosite, which
was not mutagenic in lung.
The compound 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) is an environmental contaminant and a potent
carcinogen in laboratory rodents [104]. Modulating ef-
fects of TCDD on mutagenesis was examined with male
and female Big Blue rats [105]. The rats were pre-
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then they were given aflatoxin B1 at a dose of 0.5 mg/kg
by gavage. After 2 weeks, the lacI mutation frequency
was measured. TCDD pre-treatments did not signifi-
cantly modulate the mutation frequency in male. How-
ever, the female mutation frequency was reduced to the
control level. DNA sequence analysis confirmed the ab-
sence of aflatoxin B1-induced transversion mutations in
female rats. It is speculated that sex-specific factors such
as estrogens or estrogen receptors may play a role in the
sex-dependent chemopreventive effects of TCDD against
aflatoxin B1-induced mutagenesis.Tamoxifen
As described in Carcinogens versus structurally-related
non-carcinogens, tamoxifen is widely used for adjuvant
therapy in the breast cancer patient for many years.
However, tamoxifen induces endometrial cancer in
women, and liver and endometrial tumors in rats [106].
There is no evidence, however, that tamoxifen induces
liver tumors in humans. Tamoxifen is metabolically acti-
vated to alpha-hydroxytamoxifen, which is further acit-
vated by sulfotransferase and finally induces DNA adducts.
Rat sulfotransferase activates alpha-hydroxytamoxifen but
human enzyme does not [107]. This may be the reason for
the species difference between human and rat for liver
tumorigenesis by tamoxifen. Because tamoxifen is inactive
in a battery of short-term tests for mutagenesis [108], the
in vivo mutagenicity was examined with Big Blue rats and
gpt delta rats. Tamoxifen induced lacI, cII, gpt and Spi- mu-
tations in the liver, mainly G:C to T:A transversions and −1
frameshift [58, 108–110]. Alpha-hydroxytamoxifen also
induces mutations in the liver with the spectrum of mu-
tation of G:C to T:A [22]. Thus, it appears that tamoxifen
induces liver tumors in rats via alpha-hydroxytamoxifen-
induced mutagenesis.Naturally occurring carcinogens
Several plant constituents often used for herbal treatments
were examined for the mutagenicity in vivo because of the
carcinogenicity in experimental animals and in humans.
Aristolochic acid is a nephrotoxin and carcinogenic in kid-
ney and forestomach in rodents [111]. It has been associ-
ated with the development of urothelial cancer in humans.
Male Big Blue rats were gavaged with aristolochic acid for
3 months, and the DNA adduct levels and mutations were
examined in liver (a non-target organ) and kidney (a target
organ) [112, 113]. Kidney exhibited at least two fold higher
levels of DNA adducts and mutations than liver. A:T to
T:A transversions were the predominant mutation in both
organs. In this case, higher DNA damage and mutation
frequencies were observed in the target organ than in the
non-target organ.Riddelliine is a naturally occurring pyrrolizidine alkal-
oid that induces liver hemangiosarcomas in rats and
mice [114]. Female Big Blue rats were gavaged with rid-
delliine for 12 weeks and the mutations were analyzed in
liver [115]. Mutations were induced in a dose-dependent
manner and the major mutation was G:C to T:A. Later,
liver was dissected into parenchymal and endothelial
cells and riddelliine-induced mutations were analyzed in
the cells [116]. Mutation was specifically induced in the
endothelial cells but not in the parenchymal cells. Be-
cause hemangiosarcomas are derived from endothelial
cells, the results indicate a good correlation between
mutagenesis and carcinogenesis at a cell-type level.
Oxidative damage
Oxidative stress is an important factor for in vivo mu-
tagenesis and carcinogenesis. Although KBrO3 induces
8-oxoguanine in DNA, which leads to G:C to T:A mu-
tations, in vitro genotoxicity assays suggest that KBrO3
induces deletions rather than G:C to T:A transversions
[117, 118]. Male SD gpt delta rats were given KBrO3 in
drinking water for 13 weeks and the level of 8-
oxoguanine in DNA and mutations were analyzed in
the kidney [119]. Increases of 8-oxoguanine in DNA
occurred after 1 week treatment at 500 ppm. Spi- mu-
tations were increased after 9 weeks administration at
500 ppm but no significant increases in mutation fre-
quency were observed at 500 ppm earlier than 9 weeks.
No gpt mutations were observed even at week 13. The
results suggest that deletions but not G:C to T:A are
induced by KBrO3 in kideny of rats and also that
9 weeks may be necessary to convert the induced 8-
oxoguanine in DNA to mutations. It is worth noticing,
however, that male Big Blue rats (F344) exhibited
mainly G:C to T:A transversions in kideny when they
were treated with KBrO3 in drinking water at 500 ppm
for 16 weeks [87] (see Threshold or low dose effects).
Different genetic background of rats (SD versus F344)
might affect the spectrum of mutations. When female
F344 gpt delta rats were given KBrO3 in drinking water
at 500 ppm for 9 weeks, gpt mutation frequency was
significantly increased along with slight increase of Spi-
mutations [120]. However, the spectrum of induced gpt
mutations was not predominated by G:C to T:A but
various types of mutations including −1 frameshift
were observed. Thus, it remains to be clarified what
types of mutations are induced by KBrO3 in vivo.
DNA non-reactive carcinogens (metals, asbestos and TCDD)
Several nickel compounds are carcinogenic in humans
and animals [121]. Nickel subsulfide (Ni3S2) is one of
them and induces lung tumors in F344 rats following
inhalation exposure [122]. Although Ni3S2 increased lacI
mutation frequency in in vitro Rat2 cells, it did not
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male Big Blue rats when the rats were treated by inhal-
ation through the nose [123]. Male F344 gpt delta rats
were also treated with Ni3S2 by intratracheal instillation,
but no increases in gpt and Spi- mutant frequencies were
observed in the lung [124].
Asbestos is a well-known human carcinogen that in-
duces mesothelioma and lung cancer in exposed persons
[125]. Male Big Blue rats were given amosite asbestos by
intratracheal instillation with single doses of 1 or 2 mg/
animal, or 4 weekly doses of 2 mg [126]. The in vivo
mutations were analyzed at 4 weeks or 16 weeks after
the last treatment. The average length of amosite was
more than 20 μm and the average thickness of the fiber
was 0.7 micron, leading to persistent presence in the
lung. About two fold induction of lacI mutations was
observed in the lung after 16 weeks exposure possibly
because of the persistent inflammation induced by the
treatment. Similarly, two asbestos substituent mineral
fibers, i.e., rock (stone) wool RW1 and glass wool
MMVF10, were examined for the in vivo mutagenicity
with male Big Blue rats [127]. The man-made fibers
were given to the rats by intratracheal instillation with
single doses of 1 or 2 mg/animal, or 4 weekly doses of
2 mg. Exposure of RW1 for 16 weeks increased lacI mu-
tant frequency about two-fold in the lung but MMVF10
did not. Because RW1 induces mild inflammation in the
lung, the mutagenicity may be due to DNA damage in-
duced by the inflammation.
TCDD induces various tumors in rats [104]. Male and
female Big Blue rats were exposed to 2 μg TCDD/kg by
gavage for 6 weeks but no increase in lacI mutation fre-
quency was observed in the liver of both sexes [128].
Mechanical irritation by uracil-induced urolithiasis
was examined for the in vivo mutagenicity with male Big
Blue rats [25]. The rats were fed 3 % uracil in the diet
for 50 weeks and the lacI mutation frequency was deter-
mined in the bladder. About three to five fold increases
in the mutation frequency were observed at weeks 10,
20 and 51. The mutation spectra were similar to those
of the spontaneous mutations, i.e., G:C to A:T transi-
tions at CpG sites. Therefore, it is suggested that the ele-
vation of spontaneous mutations may be due to cell
proliferations induced by the uracil treatment.
Polluted air
Diesel exhaust (DE) is a factor of air pollution and a sus-
pected cause of lung cancer and other respiratory dis-
eases [129]. Male Big Blue rats were exposed to 1 or
6 mg/m3 of DE for 4 weeks [130]. The mutant frequency
in lung was increased about five times over the control
level by exposure to six DE mg/m3 but no increases
were observed with 1 mg DE/m3. The results clearly in-
dicate that DE is mutagenic in rat lung. When male BigBlue rats were treated with a diet containing DE from 0
to 80 mg/kg for 3 weeks, no mutation induction was ob-
served in the lung although DNA adducts and DNA
strand breaks were observed [131]. The results suggest
that inhalation exposure, but not dietary exposure, is
needed to evaluate the mutagenic potential of DE in
lung. Road paving workers are exposed to bitumen
fumes, a complex mixture of various polycyclic aromatic
amines. Big Blue rats were exposed to bitumen fumes
through nose, and DNA adduct levels and mutation fre-
quencies were examined in the lung [132]. Although
DNA adducts were increased by the exposure, the muta-
tion frequencies were not enhanced. Perhaps, cell prolif-
eration is not fully induced by the treatment.
4-Monochlorobiphenyl (PCB3) is found in indoor
and outdoor air and in food [133]. Unlike polychlori-
nated biphenyls, PCB3 is more readily metabolized to
monohydroxy-PCBs by CYP drug metabolizing en-
zymes and further dihydroxy-metabolites, which can be
oxidized to quinones [134]. The mutagenicity of PCB3
and the metabolite, i.e., 4-hydroxy-PCB3, were exam-
ined with male Big Blue rats [133, 135]. The rats were
given PCB3 or 4-hydroxy-PCB3 by intraperitoneal
injection once per week for 4 weeks. In liver and lung,
the mutant frequency in PCB-3-treated rats was signifi-
cantly elevated and 4-hydroxy-PCB3 induced a non-
significant increase in the mutant frequency.
Sweet diet
Cancer incidence in colon and other organs is strongly
affected by diet and life style. Intake of sucrose-rich diet
was examined for the in vivo mutagenicity with Big Blue
rats [136]. Male Big Blue rats were fed diet with sucrose
of 3.4 % (control), 6.9, 13.8 and 34.5 % for 3 weeks with-
out affecting the overall energy and carbohydrate intake.
The cII mutation frequency was increased about two
fold in a dose-dependent manner in the colonic mucosa
but no increases in the liver. No oxidative DNA damage
was increased. Later, male Big Blue rats were fed diet
containing 30 % sucrose or the composed sugar, i.e.,
either 30 % glucose or 30 % fructose for 35 days [101].
In these experiments, however, any sugar did not signifi-
cantly increase the cII mutations in the colon and the
liver, although DNA adduct levels were increased by the
diet in both organs. It is suggested that indirect effects
such as alterations of chemical environment in colon
may account for the apparent genotoxicity.
Transgenic rats for carcinogenesis
In carcinogenesis study field, transgenic rats provide
good models too. Rats rather than mice are more fre-
quently used in chemical carcinogenesis studies for vari-
ous reasons. For example, in the liver, GST-P has been
utilized as a reliable marker for early detection of
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ent transgenic rats have been reported and utilized in
neurosciences, endocrinology and carcinogenesis fields.
Transgenic rats that are highly susceptible to carcino-
gens or exhibit high incidence of spontaneous neoplasm
are good models for screening of chemopreventive
agents and mechanism studies of carcinogenesis process.
Human c-Ha-ras proto-oncogene transgenic rats
(Hras128)
Hras128 carries a human c-Ha-ras proto-oncogene in-
cluding its own promoter region. Female Hras128 is
highly susceptible to breast carcinogens such as N-me-
thyl-N-nitrosourea (MNU) and PhIP [138, 139]. These
chemicals induced estrogen-independent breast tu-
mors because they did not respond to ovariectomy
[140]. Esophagus and bladder tumors were highly
inducible in carcinogen–treated male Hras128 [141,
142]. This Hras128 is deposited to National BioRe-
source Project (NBRP Rat No.0376), and available
from it [143]. In addition, cell lines (RMC-1, RMC-2,
RMC-3, RMC-6, RMC-11, RMC-17) derived from
Hras128 mammary adenocarcinoma are also available
from RIKEN cell bank [144].
Probasin-SV40 T antigen transgenic rats (TRAP)
TRAP expresses the simian virus 40 (SV40) large T
antigen under probasin promoter control. This animal
was established to obtain sufficient size of samples of
prostate cancer. In the male TRAP, prostate carcinomas
are developed at 100 % incidence in all lobes (ventral,
dorsolateral and anterior) before 15 weeks of age [145].
Since these tumors are androgen dependent, it is ex-
pected to utilize TRAP as a model for understanding
the mechanisms of relapsing of tumors that are andro-
gen independent. Chemopreventive studies and mech-
anism studies utilizing TRAP have been also reported
[146–148].
Connexin 32 dominant-negative transgenic rats
(Cx32Δ Tg)
Employment of the dominant negative mutants is one of
the alternatives to gene targeting in rat. Cx32Δ Tg ex-
presses a dominant negative mutant of connexin 32
(Cx32). Cx32 is a major gap junction protein in the liver.
They formed transmembrane channels between adjacent
cells. In the liver of this animal, localization of normal
connexins is disrupted and gap junction capacities are
markedly decreased [149]. Chemical-induced carcino-
genesis studies using Cx32Δtransgenic revealed that dis-
ruption of gap junctional intercellular communications
in vivo resulted in hepatocarcinogenesis and its progres-
sion [150, 151]. In addition, this transgenic rat can beutilized to mechanism studies of the onset of toxicity
which are related to cell-cell communications [149].
Transgenic rats carrying a mutated H- or K-ras gene
controlled by Cre/loxP activation (Hras250 and Kras327)
These transgenic rats express a human activated RAS
oncogene regulated by the Cre/lox system. Targeted pan-
creatic activation of the transgene was accomplished by
injection of adenovirus carrying Cre into the pancreatic
ducts and acini [152, 153]. Tumors in the model exhibit
similarities to the human pancreatic ductal adenocarcin-
oma. Hras250 is deposited to National BioResource Pro-
ject (NBRP Rat No.0568), and available [143].
Transgenic rats as carcinogenic models promise our un-
derstanding of the behavior of cancer in vivo, and will be
useful to explore new therapeutic approaches. For car-
cinogenicity studies, rasH2 mice and p53+/− mice are uti-
lized because of their high susceptibility for carcinogens
[154]. Several transgenic rats in Table 2 exhibit high
sensitivity to carcinogens and oncogenic events are eas-
ily initiated. However, their background data are still
not enough and amassed research evidence may be
needed for applying them to short-term carcinogenicity
tests. In this decade, gene-targeting technology using
rats might be about to enter a new period. Gene-
targeting technology using zinc-finger nucleases (ZFNs)
allowed generation of the first knock-out rat in 2009
[155, 156]. And, generation of knock-out rats was
achieved using rat ES cell-based technology in 2010
[157]. More recently, transcription activator-like ef-
fector nucleases (TALEN) and CRISPR/Cas9 systems
were introduced to generate knock-out and knock-in
rats [158]. The study utilizing gene-modified animals
might be stepped up by advent of knock-out rats. p53
knock out rats are expected to be highly susceptible to
chemical carcinogens. They will be applied to short-
term carcinogenicity assays even though the p53 knock
out rats and p53 knock out mice reveal differing pheno-
types [159]. Recently, the data with transgenic rats for
evaluation of carcinogenic potency of chemicals have
been remarkably accumulated. Transgenic rats for mu-
tagenesis and carcinogenesis will be principal models in
future carcinogenesis studies and drug developments.
Perspective
Development of transgenic rats for mutagenesis opened
a possibility to use them in repeat dose toxicity assays,
thereby enabling general toxicity and genotoxicity assays
in same rats [7, 160]. This approach is consistent with
the principle of 3Rs (Replacement, Refinement and
Reduction) of animal use in laboratory experiments. For
this purpose, SD and F344 gpt delta rats were compared
with non-transgenic SD and F344 rats for their toxic and
genotoxic responses to diethylnitrosamine (DEN) and
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similar levels of GST-P foci in the liver of both trans-
genic and non-transgenic rats. DEN but not DEHP
increased gpt and Spi− mutation frequency in the liver of
transgenic rats. It was concluded that SD and F344 gpt
delta rats exhibited comparable toxic and genotoxic
responses to DEHP and DEN to those with non-
transgenic SD and F344 rats. Therefore, introduction of
transgenic rats to repeat dose toxicity assays seems a
promising future of toxicology and genotoxicology stud-
ies. However, standardization of assay procedures still
needs more experimental results and discussion. For ex-
ample, 4 weeks treatment of chemicals is recommended
for gene mutation assays with transgenic rats by OECD
TG488. However, KBrO3 at 500 ppm in drinking water
needs 9 weeks to detect Spi− mutations in the kidney of
rats although 8-oxoguanien in DNA is formed by 1 week
treatment [119]. Amosite at 2 mg by intratracheal instil-
lation induced lacI mutations in the lung after treatment
period of 16 weeks but not after 1 week administration
[126]. Administration periods longer than 4 weeks may
be required to detect mutations induced by weak muta-
gens or oxidative stress such as inflammation.
Epigenetic influence of environmental chemicals is
an important research area in a field of chemical car-
cinogenesis. It is well documented that methylation of
cytosine and demethylation of 5-MC in DNA, and
methylation, acetylation and phosphorylation of his-
tone strongly affect the expression of genes and the
phenotypes [162, 163]. Perhaps epigenetic changes may
underlie the mechanisms of some of non-genotoxic
carcinogens. In fact, one of the mechanisms of nickel-
induced carcinogenesis is epigenetic alterations [164].
Although there is no literature where Big Blue rats or
gpt delta rats are used for epigenetic studies as far as
we searched, one paper reported mechanical irritation
increased mutation frequency in bladder without alter-
ation of mutation spectrum [25]. It may be interesting
to investigate the epigenetic alterations associated with
chemical treatments when the mutation frequency in-
creases without changing the mutation spectrum. Per-
haps methylation status of cytosine in DNA may be
altered by the treatments.
Recent advance in genome editing technology such as
CRISPR/Cas9 has an impact on biomedical research in-
cluding mutagenesis and carcinogenesis. In the near fu-
ture, knock-out and knock-in rats will be generated
more extensively. Aflatoxin B1 and tamoxifen induce
tumors in rats more frequently compared with mice
[18, 58]. Thus, genetic factors that affect the carcino-
genesis may be investigated with knock-out or knock-in
rats. In addition to the genome editing technology,
DNA sequence analysis with NGS is greatly evolved re-
cent years. NGS has been employed to characterizelacZ mutations in transgenic mice for mutagenesis
[165] and for exome analysis of ENU-induced germ line
mutation in gpt delta mice [166]. DNA adducts and
mutation signature in human cancer may reflect the
history of exposure of the patients to environmental
chemicals. Since sensitivity of mass spectrometer has
been increased substantially, relationships among DNA
adducts, mutations and human cancer will be more ex-
tensively studied.
Conclusions
Although mutation is an underlying mechanism of car-
cinogenesis, the literature reviewed here exhibits com-
plex relationships between in vivo mutagenesis and
carcinogenesis even for genotoxic carcinogens. The
simplest relationship between mutagenesis and carcino-
genesis is that mutations are induced only in the target
organs or sub-organs for carcinogenesis. However, mu-
tations are induced by PhIP not only in target lobe of
prostate but also in non-target lobes [41]. PhIP induces
mutations in the colon of male and female rats while it
induces tumors predominantly in male rats. Phenacetin
induced mutations in the liver (a non-target organ)
much more strongly than in the kidney (the target
organ) [52]. Similarly, TDBP induces mutations in the
cortex of kidney (a non-target site) more extensively
than outer medulla of kidney (the target site) [47].
These results suggest that the highest mutation
induction does not coincide with the localization of
tumors. The relationship between DNA adduct and
mutation is not simple too. Leucomalachite green in-
duces DNA adducts in the liver of rats but no muta-
tions are induced [79]. Bitumen fumes induces DNA
adducts in the lung without induction of detectable
mutations [132]. Obviously, factors other than mutation
such as cell proliferation strongly affect the carcinogen-
esis. Nevertheless, transgenic rat models for mutagen-
esis and carcinogenesis are useful tools for various
purposes such as regulation of chemicals, chemopreven-
tion studies and mechanistic investigations. Mutation
spectra induced by chemical exposure with transgenic rats
may be useful to interpret the mutation signatures of hu-
man cancer. Advanced sequencing technology coupled
with transgenic rat models may contribute significantly to
further development of research on chemical mutagenesis
and carcinogenesis.
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